Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 653-661

  Ratanatharathorn, Voravit ^a   Pavletic, Steven ^b   Uberti, Joseph P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

B cells APC; B cells in transplantation; BMT; GVHD; Rituximab manuscript

Indexed keywords

ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CORTICOSTEROID; DENILEUKIN DIFTITOX; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 18; INTERLEUKIN 2; KERATINOCYTE GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PENTOSTATIN; RITUXIMAB; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INFECTION; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MYASTHENIA GRAVIS; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PEMPHIGUS; PEMPHIGUS VULGARIS; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; THROMBOCYTOPENIA; WEGENER GRANULOMATOSIS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; T-LYMPHOCYTES; THROMBOCYTOPENIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 70449703353     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.07.004     Document Type: Review

References (169)

1. McLaughlin P., White C.A., Grillo-Lopez A.J., and Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12 (1775) 1763-1769
2. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 346 (2002) 235-242
3. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
4. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003) 505-511
5. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
6. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., Sanders C.J., van den Tweel J.G., and Verdonck L.F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
7. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 (2007) 273-277
8. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
9. Glennie M.J., French R.R., Cragg M.S., and Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44 (2007) 3823-3837
10. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 24 (2006) 19-28
11. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
12. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
13. Tobinai K., Kobayashi Y., and Narabayashi M. Et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 study group. Ann Oncol 9 (1998) 527-534
14. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
15. Hamaguchi Y., Uchida J., Cain D.W., et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174 (2005) 4389-4399
16. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
17. Ferrara J.L.M., and Reddy P. Pathophysiology of graft-versus-host disease. Sem Hematol 43 (2006) 3-10
18. Korngold B., and Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 148 (1978) 1687-1698
19. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
20. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 1224-1226
21. Soiffer R.J., Fairclough D., Robertson M., et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89 (1997) 3039-3047
22. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 91 (1998) 1083-1090
23. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95 (2000) 83-89
24. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
25. Drobyski W.R., Ash R.C., Casper J.T., et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83 (1994) 1980-1987
26. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 (2004) 1559-1564
27. Macmillan M.L., Couriel D., Weisdorf D.J., et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 109 (2007) 2657-2662
28. Wagner J.E., Santos G.W., Noga S.J., et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 75 (1990) 1370-1377
29. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
30. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95 (2000) 3996-4003
31. Hale G., Zhang M.J., Bunjes D., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92 (1998) 4581-4590
32. Hill G.R., Teshima T., Gerbitz A., et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104 (1999) 459-467
33. Teshima T., Ordemann R., and Reddy P. Et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. [erratum appears in Nat Med 2002 Sep;8(9):1039]. Nat Med 8 (2002) 575-581
34. Ferrara J.L. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant 21 Suppl. 3 (1998) S13-15
35. Hill G.R., Cooke K.R., Teshima T., et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102 (1998) 115-123
36. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 104 (1999) 317-325
37. Reddy P., Teshima T., Hildebrandt G., et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 101 (2003) 2877-2885
38. McCarthy Jr. P.L., Abhyankar S., Neben S., et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78 (1991) 1915-1918
39. Abhyankar S., Gilliland D.G., and Ferrara J.L. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56 (1993) 1518-1523
40. Krijanovski O.I., Hill G.R., Cooke K.R., et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94 (1999) 825-831
41. Panoskaltsis-Mortari A., Lacey D.L., Vallera D.A., and Blazar B.R. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92 (1998) 3960-3967
42. Antin J.H., Weinstein H.J., Guinan E.C., et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84 (1994) 1342-1348
43. Antin J.H., Lee S.J., Neuberg D., et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29 (2002) 373-377
44. Blazar B.R., Weisdorf D.J., Defor T., et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108 (2006) 3216-3222
45. Antin J.H., Weisdorf D., Neuberg D., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100 (2002) 3479-3482
46. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111 (2008) 2470-2475
47. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104 (2004) 649-654
48. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 680-687
49. Willenbacher W., Basara N., Blau I.W., Fauser A.A., and Kiehl M.G. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 112 (2001) 820-823
50. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 (2004) 1559-1564
51. Verholen F., Stalder M., Helg C., and Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 73 (2004) 441-446
52. Shaughnessy P.J., Bachier C., Grimley M., et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 188-193
53. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 23 (2005) 2661-2668
54. Basara N., Kiehl M.G., Blau W., et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 33 (2001) 2121-2123
55. Alousi A, Weisdorf DJ, Logan BR, et al. BMT CTN 0302: a phase II randomized trial evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in combination with corticosteroids in 180 patients (pts) with newly diagnosed acute graft vs. host disease (aGVHD). ASH Annual Meeting Abstracts 2008;112:55-.
56. Ringden O., Witherspoon R., Storb R., Ekelund E., and Thomas E.D. B cell function in human marrow transplant recipients assessed by direct and indirect hemolysis-in-gel assays. J Immunol 123 (1979) 2729-2734
57. Ringden O., Witherspoon R.P., Storb R., Ekelund E., and Thomas E.D. Increased in vitro B-cell IgG secretion during acute graft-versus-host disease and infection. Observations in 50 human marrow transplant recipients. Blood 55 (1980) 179-186
58. Tsoi M.S., Storb R., Jones E., et al. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol 120 (1978) 1485-1492
59. Ron Y., De Baetselier P., Gordon J., Feldman M., and Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. Eur J Immunol 11 (1981) 964-968
60. Ron Y., De Baetselier P., Tzehoval E., Gordon J., Feldman M., and Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells. Eur J Immunol 13 (1983) 167-171
61. Tzehoval E., De Baetselier P., Ron Y., Tartakovsky B., Feldman M., and Segal S. Splenic B cells function as immunogenic antigen-presenting cells for the induction of effector T cells. Eur J Immunol 13 (1983) 89-94
62. Janeway Jr. C.A., Ron J., and Katz M.E. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 138 (1987) 1051-1055
63. Schultz K.R., Paquet J., Bader S., and HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 16 (1995) 289-295
64. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
65. Hainsworth J.D., Burris III H.A., Morrissey L.H., et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95 (2000) 3052-3056
66. Romaguera J.E., Fayad L., and Rodriguez M.A. et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.[erratum appears in J Clin Oncol. 2006 Feb 1;24(4):724]. J Clin Oncol 23 (2005) 7013-7023
67. Iori A.P., Torelli G.F., De Propris M.S., et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 85 (2008) 386-390
68. Ratanatharathorn V., Logan B., Wang D., et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 145 (2009) 9
69. Bertrand Y., Landais P., Friedrich W., et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the European society for immunodeficiency. J Pediat 134 (1999) 740-748
70. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112 (2008) 1147-1150
71. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110 (2007) 2924-2930
72. Bour-Jordan H., and Bluestone J.A. B cell depletion: a novel therapy for autoimmune diabetes?. J Clin Invest 117 (2007) 3642-3645
73. Albert D., Dunham J., Khan S., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheumat Dis 67 (2008) 1724-1731
74. Gottenberg J.E., Guillevin L., Lambotte O., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheumat Dis 64 (2005) 913-920
75. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthrit Rheumat 48 (2003) 455-459
76. Gleichmann E., Van Elven E.H., and Van der Veen J.P. A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur J Immunol 12 (1982) 152-159
77. der Veen F.M., Kiesel U., Poels L., et al. Further evidence against random polyclonal antibody formation in mice with lupus-like graft-vs-host disease. J Immunol 132 (1984) 1814-1820
78. Jaffee B.D., and Claman H.N. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77 (1983) 1-12
79. Anderson B.E., McNiff J.M., Matte C., Athanasiadis I., Shlomchik W.D., and Shlomchik M.J. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104 (2004) 1565-1573
80. Sakoda Y., Hashimoto D., Asakura S., et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109 (2007) 1756-1764
81. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 107 (2006) 2993-3001
82. Ratanatharathorn V., Ayash L., Lazarus H.M., Fu J., and Uberti J.P. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 28 (2001) 121-129
83. Kapur R., Ebeling S., and Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica 93 (2008) 1702-1711
84. Ratanatharathorn V., Carson E., Reynolds C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Int Med 133 (2000) 275-279
85. Godeau B., Porcher R., Fain O., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 112 (2008) 999-1004
86. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003) 505-511
87. Reddy P., Johnson K., Uberti J.P., et al. Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 38 (2006) 351-357
88. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103 (2004) 353-359
89. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105 (2005) 2973-2978
90. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 199 (2004) 1133-1142
91. Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
92. Liossis S.-.N.C., and Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127 (2008) 280-285
93. Gorelik L., Gilbride K., Dobles M., Kalled S.L., Zandman D., and Scott M.L. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 198 (2003) 937-945
94. Mackay F., and Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2 (2002) 465-475
95. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 13 (2007) 6107-6114
96. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113 (2009) 3865-3874
97. Anasetti C., Rybka W., Sullivan K.M., and Banaji M. Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia Blood 73 (1989) 1054-1058
98. Looney R.J. Treating human autoimmune disease by depleting B cells. Ann Rheumat Dis 61 (2002) 863-866
99. Kazkaz H., and Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 4 (2004) 398-402
100. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
101. Zecca M., Nobili B., Ramenghi U., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 (2003) 3857-3861
102. Zaja F., Iacona I., and Masolini P. Et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. [erratum appears in Haematologica 2002 Mar;87(3):336]. Haematologica 87 (2002) 189-195
103. Ramanathan S., Koutts J., and Hertzberg M.S. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 78 (2005) 123-126
104. Radhi M., Rumelhart S., Tatman D., and Goldman F. Severe autoimmune hemolytic anemia after unrelated umbilical cord blood transplant for familial hemophagocytic lymphohistiocytosis: significant improvement after treatment with rituximab. J Pediat Hematol/Oncol 29 (2007) 125-127
105. Galor A., and O'Brien T. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome. Int J Hematol 78 (2003) 335-336
106. D'Arena G., Laurenti L., Capalbo S., et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 81 (2006) 598-602
107. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 99 (2002) 1092-1094
108. Sharma V.R., Fleming D.R., and Slone S.P. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96 (2000) 1184-1186
109. Zecca M., De Stefano P., Nobili B., and Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97 (2001) 3995-3997
110. Willems M., Haddad E., and Niaudet P. Et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. [erratum appears in J Pediatr. 2006 Oct;149(4):586]. J Pediat 148 (2006) 623-627
111. Ahuja A., Shupe J., Dunn R., Kashgarian M., Kehry M.R., and Shlomchik M.J. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179 (2007) 3351-3361
112. Pego-Reigosa J.M., and Isenberg D.A. Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opin Investig Drugs 17 (2008) 31-41
113. Edwards J.C.W., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 350 (2004) 2572-2581
114. Leandro M.J., Edwards J.C.W., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheumat Dis 61 (2002) 883-888
115. Taylor P.C. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3 (2003) 323-328
116. Brulhart L., Ciurea A., Finckh A., et al. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. Ann Rheumat Dis 65 (2006) 1255-1257
117. Dupuy A., Viguier M., Bedane C., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140 (2004) 91-96
118. Cianchini G., Corona R., Frezzolini A., Ruffelli M., Didona B., and Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143 (2007) 1033-1038
119. Chung L., Genovese M.C., and Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143 (2007) 763-767
120. Wylam M.E., Anderson P.M., Kuntz N.L., and Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediat 143 (2003) 674-677
121. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 5 (2005) 303-307
122. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., and Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45 (2006) 1432-1436
123. Sanchez-Cano D., Callejas-Rubio J.L., and Ortego-Centeno N. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. JCR J Clin Rheumatol 14 (2008) 92-93
124. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., Sanders C.J., van den Tweel J.G., and Verdonck L.F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
125. Carella A.M., Biasco S., Nati S., Congiu A., and Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leuk Lymph 48 (2007) 623-624
126. Mohty M., Marchetti N., El-Cheikh J., Faucher C., Furst S., and Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 41 (2008) 909-911
127. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20 (2006) 172-173
128. Hu C.-y., Rodriguez-Pinto D., and Du W. Et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117 (2007) 3857-3867
129. von Bonin M., Oelschlagel U., Radke J., et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86 (2008) 875-879
130. Vellenga E., and van Putten W.L.J. Van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 111 (2008) 537-543
131. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111 (2008) 5530-5536
132. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 (2003) 4407-4412
133. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 26 (2007) 3603-3613
134. Coiffier B. New treatment strategies in lymphomas: aggressive lymphomas. Annals of Hematology 83 Suppl. 1 (2004) S73-74
135. Lee H.J., Gulbis A., De Padua Silva L., et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42 (2008) 67-69
136. Musso M., Porretto F., Crescimanno A., Polizzi V., and Scalone R. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 33 (2004) 769-771
137. Selleri C., Raiola A., De Rosa G., et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant 22 (1998) 605-607
138. Helbig G., Stella-Holowiecka B., Krawczyk-Kulis M., et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica 90 Suppl. (2005) ECR33
139. Kako S., Kanda Y., Oshima K., et al. Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol 83 (2008) 247-249
140. Maschan A.A., Skorobogatova E.V., Balashov D.N., et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 30 (2002) 405-407
141. Raj K., Narayanan S., Augustson B., et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 35 (2005) 299-301
142. Faye A., Quartier P., Reguerre Y., et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115 (2001) 112-118
143. Ghobrial I.M., Habermann T.M., Ristow K.M., et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymph 46 (2005) 191-196
144. Kordelas L., Trenschel R., Koldehoff M., Elmaagacli A., and Beelen D.W. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 31 (2008) 691-693
145. Dayde D., Ternant D., Ohresser M., et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113 (2009) 3765-3772
146. Olivieri A., Lucesole M., Capelli D., et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 627-636
147. Cartron G., Zhao-Yang L., Baudard M., et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 26 (2008) 2725-2731
148. Castillo J., Winer E., and Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36 (2008) 755-768
149. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discover 5 (2006) 564-576
150. Halpern W.G., Lappin P., Zanardi T., et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 91 (2006) 586-599
151. Nestorov I., Munafo A., Papasouliotis O., and Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48 (2008) 406-417
152. Ansell S.M., Witzig T.E., Inwards D.J., et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 14 (2008) 1105-1110
153. Furie R., Stohl W., Ginzler E., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthrit Res Therapy 10 (2008) 109
154. Tak P.P., Thurlings R.M., Rossier C., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthrit Rheumat 58 (2008) 61-72
155. Cohen S.B. Updates from B cell trials: efficacy. J Rheumatol Suppl 77 (2006) 12-17
156. Friedberg J.W., Neuberg D., Gribben J.G., et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117 (2002) 828-834
157. Gluck W.L., Hurst D., Yuen A., et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10 (2004) 2253-2264
158. Gonzalez-Stawinski G.V., Yu P.B., Love S.D., Parker W., and Davis Jr. R.D. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98 (2001) 175-179
159. van der Kolk L.E., Baars J.W., Prins M.H., et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100 (2002) 2257-2259
160. Norlin A.C., Sairafi D., Mattsson J., Ljungman P., Ringden O., and Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41 (2008) 267-273
161. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122 (2007) 62-74
162. Matteucci P., Magni M., Di Nicola M., Carlo-Stella C., Uberti C., and Gianni A.M. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100 (2002) 1104-1105
163. Freim Wahl S.G., Folvik M.R., and Torp S.H. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26 (2007) 68-73
164. Kranick S.M., Mowry E.M., and Rosenfeld M.R. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69 (2007) 704-706
165. Rey J., Belmecheri N., Bouayed N., et al. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab. Haematologica 92 (2007) e101
166. Harris H.E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology 47 (2008) 224-225
167. Kamar N., Mengelle C., and Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 9 (2009) 244-245
168. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 (2009) 4834-4840
169. Yeo W., Chan T.C., Leung N.W.Y., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27 (2009) 605-611